Opinions

Ireland looks to get ahead by securing AstraZeneca vaccine supply before EMA recommendation. Others could follow suit with supply a constraint.

The U.S. dollar is also in focus.

The EU continues to disappoint with low vaccination rates, while Brazil and India begin vaccination drives to bring the pandemic under control.

COVID-19 vaccination rates remain low across the EU. The EMA looks to fast track the authorization of the AstraZeneca vaccine to ramp up vaccinations.

China’s Sinovac vaccine comes under scrutiny following clinical trial results from Brazil. Johnson & Johnson remains on track, however, to deliver a single dose vaccine in Q1.

The UK Government’s ramp up of vaccination rates leaves the EU red faced. A global effort is needed, however, to bring an end to the pandemic…

Will Trump make it to Inauguration Day? It will be an interesting couple of days in U.S politics. If Trump makes it then it sends a big anti-democracy message…

What I’ve concluded is that Bitcoin analysts love momentum when its breaking out to the upside, but when it comes to sell-offs, very little is written.

As governments look to ramp up vaccination rates, some lag behind others. Greater availability of existing vaccines and a single dose are a must.

Trump brings democracy to its knees, weighing on the Greenback this week. There could be more twists and turns before Inauguration Day…

Vaccination rates are raising eyebrows, as new COVID-19 cases continue to spike. Failure to materially ramp up vaccinations should be of concern.

Trump signs the aid package and spending bill as lawmakers ready to override his Defence Bill veto.

Bitcoin had an impressive year in 2020, assuming there is no year-end meltdown. More of the same would deliver $100,000 for the bulls…

The EU continues to give the markets hope. Key hurdles remain, however, including access to UK fisheries. Is there really a resolution to this?

The Latest On Monday, the EU’s European Medicines Agency (“EMA”) recommended the authorization of the BioNTech/Pfizer Inc. vaccine. An assessment report, with details of the EMA’s evaluation of Comirnaty, and the full risk management plan is due out in the coming days. According to the EMA report, the recommendation was

Moderna Inc. and the FDA will be in focus, with AstraZeneca also in search of approval in the UK this week.

FDA feels the heat from the Whitehouse, as the U.S readies to begin Operation Warp. Vaccine availability will be an issue near-term, however.

A no-deal scenario the likely outcome. That’s the news of the day. The ever eternal optimists will be hoping for good news before the markets close…

The FDA is due to review BioNTech/Pfizer Inc.’s vaccine later today. Approval is a must to support riskier assets and give some hope to the worst affected.

The British PM and EU President agree to a Sunday deadline. Make or break talks will now continue and the Pound could come under fire…